{"id":"high-dosage-sars-cov-2-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains chemically inactivated whole SARS-CoV-2 virions that cannot replicate. When administered at higher doses than standard formulations, it aims to elicit a stronger humoral and cellular immune response, generating neutralizing antibodies and T-cell responses against viral spike and other structural proteins. This enhanced immunogenicity is intended to provide improved protection against infection and severe COVID-19.","oneSentence":"This inactivated SARS-CoV-2 vaccine stimulates the immune system to produce antibodies and cellular immunity against the virus by presenting inactivated viral particles.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:47:46.764Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 caused by SARS-CoV-2"}]},"trialDetails":[{"nctId":"NCT05212610","phase":"PHASE4","title":"Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2022-03-21","conditions":"COVID-19, Corona Virus Infection","enrollment":137},{"nctId":"NCT07280858","phase":"PHASE1, PHASE2","title":"A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.","status":"RECRUITING","sponsor":"SK Bioscience Co., Ltd.","startDate":"2026-01-28","conditions":"Healthy Participants, Sarbecovirus","enrollment":368},{"nctId":"NCT04639466","phase":"PHASE1, PHASE2","title":"A Synthetic MVA-based SARS-CoV-2 Vaccine, GEO-CM04S1, for the Prevention of COVID-19 Infection","status":"COMPLETED","sponsor":"GeoVax, Inc.","startDate":"2020-11-19","conditions":"COVID-19 Infection","enrollment":119},{"nctId":"NCT06821061","phase":"PHASE1, PHASE2","title":"A Study to Learn About How the Flu and COVID-19 Vaccines Act in Healthy People","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2025-02-10","conditions":"Influenza, COVID-19 (Coronavirus Disease 2019)","enrollment":2650},{"nctId":"NCT04869592","phase":"PHASE1, PHASE2","title":"A Clinical Trial to Evaluate the Recombinant SARS-CoV-2 Vaccine (CHO Cell) for COVID-19","status":"COMPLETED","sponsor":"National Vaccine and Serum Institute, China","startDate":"2021-04-25","conditions":"COVID-19","enrollment":3100},{"nctId":"NCT06821126","phase":"PHASE1, PHASE2","title":"Study Comparing Safety and Immunogenicity of Intranasal COVID-19 Vaccine and mRNA Booster in Healthy Adults","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-05-09","conditions":"Healthy","enrollment":238},{"nctId":"NCT06851611","phase":"PHASE1","title":"The Safety and Antibody Response of the Nasal COV2 Vaccine Against the SARS-CoV-2 Virus","status":"COMPLETED","sponsor":"Rokote Laboratories Finland Oy","startDate":"2025-01-21","conditions":"COVID19, Sars-Cov-2","enrollment":40},{"nctId":"NCT05960097","phase":"PHASE2","title":"A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-08-01","conditions":"SARS-CoV-2, COVID-19","enrollment":692},{"nctId":"NCT04537208","phase":"PHASE1, PHASE2","title":"Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-03","conditions":"COVID-19 (Healthy Volunteers)","enrollment":441},{"nctId":"NCT05220397","phase":"PHASE3","title":"Janssen Ad26.CoV2.S Vaccine Booster in Kidney Transplant Recipients","status":"TERMINATED","sponsor":"Mark Stegall","startDate":"2022-04-11","conditions":"Kidney Transplant Recipient","enrollment":468},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT04839042","phase":"PHASE1","title":"A Phase 1, First-In-Human Study of the Investigational COVID-19 Vaccine SC-Ad6-1 in Healthy Volunteers","status":"COMPLETED","sponsor":"Moat Biotechnology Corporation","startDate":"2021-06-28","conditions":"Covid19","enrollment":196},{"nctId":"NCT04297917","phase":"PHASE1","title":"First in Human Study of ChAdOx1-HBV in Healthy Participants and Participants With Chronic hepB Infection","status":"COMPLETED","sponsor":"Barinthus Biotherapeutics","startDate":"2019-02-10","conditions":"Hepatitis B, Healthy","enrollment":47},{"nctId":"NCT07113106","phase":"PHASE1, PHASE2","title":"Dose Escalation Trial of CD40.Pan.CoV Vaccine, Adjuvanted or Not, as a Booster in Adult Healthy Volunteers","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2025-06-18","conditions":"Healthy Volunteers","enrollment":48},{"nctId":"NCT07086222","phase":"PHASE4","title":"Efficacy and Safety of NVX-CoV2705","status":"NOT_YET_RECRUITING","sponsor":"Novavax","startDate":"2025-11-10","conditions":"COVID-19, Sars-CoV-2 Infection","enrollment":6500},{"nctId":"NCT06291857","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novavax","startDate":"2024-12-09","conditions":"COVID-19","enrollment":9320},{"nctId":"NCT05094609","phase":"PHASE1","title":"Phase 1 Trial of ChAd68 and Ad5 Adenovirus COVID-19 Vaccines Delivered by Aerosol","status":"COMPLETED","sponsor":"McMaster University","startDate":"2022-01-03","conditions":"COVID-19, SARS-CoV2 Infection","enrollment":36},{"nctId":"NCT05091307","phase":"PHASE3","title":"A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-11-02","conditions":"COVID-19 Prevention","enrollment":861},{"nctId":"NCT04473690","phase":"PHASE1, PHASE2","title":"KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers","status":"COMPLETED","sponsor":"KBio Inc","startDate":"2020-12-30","conditions":"Covid19","enrollment":102},{"nctId":"NCT04668339","phase":"PHASE2","title":"A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults","status":"TERMINATED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2021-01-07","conditions":"Covid19, SARS-CoV Infection, Corona Virus Infection","enrollment":581},{"nctId":"NCT05184114","phase":"NA","title":"Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2021-10-04","conditions":"COVID-19, Myocarditis","enrollment":162},{"nctId":"NCT06255626","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-05-27","conditions":"COVID-19","enrollment":215},{"nctId":"NCT05181709","phase":"PHASE1","title":"A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.","status":"COMPLETED","sponsor":"Sean Liu","startDate":"2022-02-09","conditions":"SARS-CoV-2","enrollment":35},{"nctId":"NCT05067933","phase":"PHASE2","title":"A Ph 2 Trial With an Oral Tableted COVID-19 Vaccine","status":"TERMINATED","sponsor":"Vaxart","startDate":"2021-10-22","conditions":"COVID-19","enrollment":66},{"nctId":"NCT06695117","phase":"PHASE1, PHASE2","title":"Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-11-19","conditions":"COVID-19 Immunization, Influenza Immunization","enrollment":980},{"nctId":"NCT05013983","phase":"PHASE1, PHASE2","title":"Clinical Trial of Recombinant COVID-19 Vaccine (Sf9 Cells) in Children and Adolescents","status":"WITHDRAWN","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2024-07","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05280158","phase":"PHASE1, PHASE2","title":"High-Dose Moderna mRNA-1273 Booster Study for Lung Transplant Recipients","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2022-03-10","conditions":"Lung Transplant Recipient, SARS-CoV-2, Immunosuppression","enrollment":19},{"nctId":"NCT05765604","phase":"PHASE1","title":"Phase I Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell) (WSK-V102)","status":"COMPLETED","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2023-03-14","conditions":"COVID-19","enrollment":72},{"nctId":"NCT05043259","phase":"PHASE1, PHASE2","title":"Heterologous Prime-boost Immunization with an Aerosolised Adenovirus Type-5 Vector-based COVID-19 Vaccine (Ad5-nCoV) After Priming with an Inactivated SARS-CoV-2 Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2021-08-14","conditions":"COVID-19","enrollment":423},{"nctId":"NCT05113862","phase":"PHASE1","title":"A Phase-I Study of a Nanoparticle-based Peptide Vaccine Against SARS-CoV-2","status":"COMPLETED","sponsor":"Gylden Pharma Ltd","startDate":"2022-01-10","conditions":"Coronavirus, SARS-CoV-2 Infection, COVID-19","enrollment":26},{"nctId":"NCT05586178","phase":"NA","title":"Information Provision and Consistency Framing to Increase COVID-19 Booster Uptake","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2022-10-18","conditions":"COVID-19, Vaccines","enrollment":177720},{"nctId":"NCT05373472","phase":"PHASE2","title":"Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2022-07-06","conditions":"COVID-19","enrollment":150},{"nctId":"NCT05373485","phase":"PHASE1","title":"Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2022-05-17","conditions":"COVID-19","enrollment":43},{"nctId":"NCT06441955","phase":"PHASE4","title":"Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.","status":"RECRUITING","sponsor":"Well- Konnect Healthcare Services and Research Firm","startDate":"2024-03-01","conditions":"COVID-19, Long Haul","enrollment":100},{"nctId":"NCT04710303","phase":"PHASE1","title":"COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults","status":"COMPLETED","sponsor":"ImmunityBio, Inc.","startDate":"2021-03-02","conditions":"Covid19","enrollment":41},{"nctId":"NCT05271929","phase":"PHASE3","title":"Early High-Titre Convalescent Plasma in Clinically Vulnerable Individuals With Mild COVID-19","status":"TERMINATED","sponsor":"Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen","startDate":"2022-04-01","conditions":"COVID-19","enrollment":120},{"nctId":"NCT05132907","phase":"PHASE1","title":"Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein","status":"COMPLETED","sponsor":"HDT Bio","startDate":"2022-01-24","conditions":"SARS-CoV2 Infection","enrollment":48},{"nctId":"NCT05799651","phase":"PHASE1","title":"Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Glycovax Pharma Inc.","startDate":"2023-04-28","conditions":"SARS-CoV-2","enrollment":36},{"nctId":"NCT05911061","phase":"PHASE3","title":"A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination","status":"NOT_YET_RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2024-12-30","conditions":"COVID-19","enrollment":4950},{"nctId":"NCT05770180","phase":"PHASE2","title":"Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)","status":"COMPLETED","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2023-03-30","conditions":"COVID-19","enrollment":450},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05031468","phase":"","title":"Multisite Observational Maternal and Infant Study for COVID-19","status":"COMPLETED","sponsor":"Emory University","startDate":"2021-07-06","conditions":"COVID-19","enrollment":562},{"nctId":"NCT04880447","phase":"","title":"Special Investigation of COMIRNATY in the Population With Underlying Diseases","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-05-26","conditions":"COVID-19","enrollment":1075},{"nctId":"NCT04563702","phase":"PHASE1","title":"Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects","status":"COMPLETED","sponsor":"Vaxart","startDate":"2020-09-21","conditions":"Covid19","enrollment":35},{"nctId":"NCT05696067","phase":"PHASE1, PHASE2","title":"Evaluation of Corfluvec Vaccine for the Prevention of COVID-19 in Healthy Volunteers","status":"COMPLETED","sponsor":"Tatyana Zubkova","startDate":"2022-09-13","conditions":"COVID-19","enrollment":200},{"nctId":"NCT05604690","phase":"PHASE1","title":"Safety and Efficacy of Intranasal Administration of Avacc 10 Vaccine Against COVID-19 in Healthy Volunteers","status":"COMPLETED","sponsor":"Intravacc B.V.","startDate":"2022-11-03","conditions":"COVID-19","enrollment":40},{"nctId":"NCT05894525","phase":"","title":"Post-Marketing Safety Study in Japan in Participants With High Risk of Severe Exacerbation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-15","conditions":"SARS-CoV-2","enrollment":8844},{"nctId":"NCT05894499","phase":"","title":"Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-15","conditions":"SARS-CoV-2","enrollment":13309},{"nctId":"NCT05894590","phase":"","title":"Post-Marketing Non-Acute Safety Study in Japan After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons at High Risk of Severe COVID-19","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-15","conditions":"SARS-CoV-2","enrollment":13680},{"nctId":"NCT05148091","phase":"PHASE1, PHASE2","title":"The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults","status":"COMPLETED","sponsor":"Sinocelltech Ltd.","startDate":"2021-12-01","conditions":"COVID-19","enrollment":478},{"nctId":"NCT04954287","phase":"PHASE1","title":"Phase 1 Study of Intranasal PIV5 COVID-19 Vaccine Expressing SARS-CoV-2 Spike Protein in Healthy Adults and Adolescents","status":"COMPLETED","sponsor":"CyanVac LLC","startDate":"2021-08-06","conditions":"Covid19","enrollment":72},{"nctId":"NCT04642638","phase":"PHASE2, PHASE3","title":"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure","status":"TERMINATED","sponsor":"Inovio Pharmaceuticals","startDate":"2020-11-30","conditions":"Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID-19 Disease","enrollment":1307},{"nctId":"NCT04816643","phase":"PHASE2, PHASE3","title":"A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2021-03-24","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":11837},{"nctId":"NCT04608305","phase":"PHASE1, PHASE2","title":"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine","status":"COMPLETED","sponsor":"Israel Institute for Biological Research (IIBR)","startDate":"2020-10-28","conditions":"Covid19","enrollment":843},{"nctId":"NCT06113744","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine","status":"UNKNOWN","sponsor":"CNBG-Virogin Biotech (Shanghai) Ltd.","startDate":"2023-03-10","conditions":"SARS-CoV-2 Infection","enrollment":164},{"nctId":"NCT04977479","phase":"PHASE2","title":"The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-08","conditions":"Systemic Allergic Reaction","enrollment":20},{"nctId":"NCT04470609","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged ⩾60 Years","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2020-07-10","conditions":"COVID-19","enrollment":471},{"nctId":"NCT04412538","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2020-05-15","conditions":"COVID-19","enrollment":942},{"nctId":"NCT05663086","phase":"PHASE2","title":"Immunogenicity and Safety of COVID-19 Vaccine in Population Aged 18 Years and Above","status":"WITHDRAWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2023-01-07","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05254236","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated Vaccine in Healthy Adults in in Hong Kong","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-02-10","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04523571","phase":"PHASE1","title":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"BioNTech SE","startDate":"2020-07-28","conditions":"SARS-CoV-2","enrollment":144},{"nctId":"NCT04679909","phase":"PHASE1","title":"Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study)","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2021-02-25","conditions":"Healthy Volunteers","enrollment":92},{"nctId":"NCT05047692","phase":"PHASE1","title":"Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Cellid Co., Ltd.","startDate":"2021-09-09","conditions":"Covid19","enrollment":40},{"nctId":"NCT04666012","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Cellid Co., Ltd.","startDate":"2020-12-29","conditions":"COVID-19","enrollment":150},{"nctId":"NCT04871737","phase":"PHASE1","title":"Study of a Live rNDV Based Vaccine Against COVID-19","status":"COMPLETED","sponsor":"Laboratorio Avi-Mex, S.A. de C.V.","startDate":"2021-05-20","conditions":"SARS-CoV-2 Infection","enrollment":91},{"nctId":"NCT05950776","phase":"PHASE2","title":"COVID-19 Trial of the Candidate Vaccine MVA-SARS-2-S in Adults","status":"WITHDRAWN","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-01-15","conditions":"Covid19","enrollment":""},{"nctId":"NCT05420077","phase":"PHASE1","title":"Safety and Immunogenicity of RVM-V001 in Healthy Individuals Previously Vaccinated With BNT162b2 and mRNA-1273","status":"TERMINATED","sponsor":"RVAC Medicines (US), Inc.","startDate":"2022-09-12","conditions":"Infectious Disease, COVID-19","enrollment":13},{"nctId":"NCT04552366","phase":"PHASE1","title":"A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults","status":"COMPLETED","sponsor":"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China","startDate":"2020-09-29","conditions":"COVID-19","enrollment":149},{"nctId":"NCT05844202","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention","status":"COMPLETED","sponsor":"Alvea Holdings, LLC","startDate":"2022-06-27","conditions":"Sars-CoV-2 Infection","enrollment":130},{"nctId":"NCT05706324","phase":"PHASE1","title":"Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Wuhan BravoVax Co., Ltd.","startDate":"2023-06","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04742738","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2021-01-20","conditions":"COVID-19 (Healthy Volunteers)","enrollment":260},{"nctId":"NCT04866069","phase":"PHASE1","title":"Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults","status":"TERMINATED","sponsor":"Osman ERGANIS, PhD, Prof","startDate":"2021-04-25","conditions":"Covid19","enrollment":50},{"nctId":"NCT04760743","phase":"PHASE1","title":"Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)","status":"COMPLETED","sponsor":"SK Bioscience Co., Ltd.","startDate":"2020-12-17","conditions":"COVID-19 (Healthy Volunteers)","enrollment":50},{"nctId":"NCT04604743","phase":"NA","title":"Clinic-based HPV and COVID-19 Vaccine Promoting Intervention for AfAm Adolescents in Alabama","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2021-04-20","conditions":"Vaccine Refusal","enrollment":""},{"nctId":"NCT05193279","phase":"PHASE2, PHASE3","title":"Safety and Immunogenicity of SCB-2019 in Children <18 Years of Age","status":"WITHDRAWN","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-10-05","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05549206","phase":"NA","title":"A Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in Chinese People","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-04","conditions":"SARS-CoV-2","enrollment":350},{"nctId":"NCT05552573","phase":"PHASE1","title":"Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above","status":"UNKNOWN","sponsor":"Guangzhou Patronus Biotech Co., Ltd.","startDate":"2022-07-19","conditions":"COVID-19","enrollment":100},{"nctId":"NCT05550142","phase":"NA","title":"A Preliminary Exploratory Cohort Study of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine in Participants Aged 18 Years and Over in China","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2022-09-16","conditions":"SARS-CoV-2","enrollment":54},{"nctId":"NCT05547243","phase":"NA","title":"A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in China","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2022-09-26","conditions":"SARS-CoV-2","enrollment":350},{"nctId":"NCT05545683","phase":"PHASE3","title":"Safety and Immunogenicity of Inactivated Heterologous Booster Vaccination","status":"WITHDRAWN","sponsor":"Centro de Estudios en Infectogía Pediatrica","startDate":"2022-12-01","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04840992","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of Recombinant Novel Coronavirus (COVID-19) Vaccine (Adenovirus Type 5 Vector) for Inhalation","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-21","conditions":"COVID-19","enrollment":840},{"nctId":"NCT05156632","phase":"PHASE3","title":"Efficacy,Immunogenicity and Safety of COVID-19 Vaccine , Inactivated Booster Dose in Adults Aged 18 Years and Above","status":"WITHDRAWN","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2023-02-20","conditions":"COVID-19","enrollment":""},{"nctId":"NCT05037188","phase":"PHASE1, PHASE2","title":"Clinical Study of the Safety and Immunogenicity of a Recombinant Viral Vector AAV5 (Adeno-Associated Virus Type 5 )-RBD (Receptor Binding Domain)-S Vaccine for the Prevention of Coronavirus Infection (COVID-19)","status":"TERMINATED","sponsor":"Biocad","startDate":"2021-08-10","conditions":"Coronavirus Infection, COVID-19","enrollment":50},{"nctId":"NCT04895449","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-ST Against COVID-19","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2021-07-16","conditions":"Covid19","enrollment":43},{"nctId":"NCT05144139","phase":"PHASE1, PHASE2","title":"A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above","status":"COMPLETED","sponsor":"Stemirna Therapeutics","startDate":"2021-12-03","conditions":"COVID-19 Pandemic","enrollment":480},{"nctId":"NCT05364047","phase":"PHASE1","title":"Clinical Trial of SARS-CoV-2 mRNA Vaccine in China","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2021-07-31","conditions":"COVID-19","enrollment":144},{"nctId":"NCT04993586","phase":"PHASE1, PHASE2","title":"Phase I/II Study of COVID-19 DNA Vaccine (AG0302-COVID19 High-dose)","status":"COMPLETED","sponsor":"AnGes, Inc.","startDate":"2021-07-29","conditions":"COVID-19 Lower Respiratory Infection","enrollment":422},{"nctId":"NCT05599802","phase":"PHASE1","title":"Clinical Study of SARS-CoV-2 Variant mRNA Vaccine in Healthy Participants","status":"UNKNOWN","sponsor":"AIM Vaccine Co., Ltd.","startDate":"2023-02","conditions":"SARS-CoV-2","enrollment":144},{"nctId":"NCT04816019","phase":"PHASE1","title":"A Study of Intranasal ChAdOx1 nCOV-19","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-04-01","conditions":"Coronavirus","enrollment":42},{"nctId":"NCT05171946","phase":"PHASE1","title":"Phase-I Study to Evaluate the Safety and Immunogenicity of a Prophylactic pDNA Vaccine Candidate Against COVID-19 in Healthy Adults","status":"UNKNOWN","sponsor":"Iman Almansour","startDate":"2022-11-20","conditions":"Safety, Vaccine Reaction, Vaccine Adverse Reaction","enrollment":30},{"nctId":"NCT05526183","phase":"PHASE1","title":"Phase I Clinical Trial With New SARS-CoV-2 CoVacHGMix Type 5 Adenoviral Vector Vaccine","status":"UNKNOWN","sponsor":"Ankara City Hospital Bilkent","startDate":"2022-01-21","conditions":"COVID-19","enrollment":36},{"nctId":"NCT04773067","phase":"PHASE2","title":"A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers","status":"TERMINATED","sponsor":"United Biomedical Inc., Asia","startDate":"2021-01-30","conditions":"COVID-19","enrollment":3877},{"nctId":"NCT04545749","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","status":"COMPLETED","sponsor":"United Biomedical Inc., Asia","startDate":"2020-09-25","conditions":"COVID-19","enrollment":60},{"nctId":"NCT05165966","phase":"PHASE4","title":"Safety and Immunogenicity Study of Booster Vaccination in Different Doses of COVID-19 Vaccine (Vero Cell),Inactivated for Prevention of COVID-19","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2021-10-20","conditions":"COVID-19","enrollment":340},{"nctId":"NCT04383574","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19)","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2020-05-22","conditions":"COVID-19","enrollment":422},{"nctId":"NCT05150496","phase":"PHASE2","title":"Immunogenicity and Safety Study of the 3rd Booster Dose Using the High or Medium Dose of Inactivated (CoronaVac®) Vaccine in Healthy Adults in Turkey","status":"SUSPENDED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2022-12-15","conditions":"COVID-19","enrollment":640},{"nctId":"NCT04892888","phase":"","title":"Survey of the Moderna COVID-19 Vaccine in People at High-Risk of Developing Severe COVID-19 Symptoms","status":"WITHDRAWN","sponsor":"Takeda","startDate":"2022-08-01","conditions":"Coronavirus Disease (COVID-19)","enrollment":""},{"nctId":"NCT04822025","phase":"PHASE2","title":"A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Elderly Adults","status":"COMPLETED","sponsor":"Medigen Vaccine Biologics Corp.","startDate":"2021-05-20","conditions":"Covid19 Vaccine","enrollment":420},{"nctId":"NCT04619628","phase":"PHASE1","title":"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2020-12-11","conditions":"COVID-19","enrollment":48},{"nctId":"NCT04530656","phase":"PHASE1","title":"Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell)","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2020-08-28","conditions":"COVID-19","enrollment":168}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CoronaVac"],"phase":"marketed","status":"active","brandName":"High-dosage SARS-CoV-2 vaccine","genericName":"High-dosage SARS-CoV-2 vaccine","companyName":"Sinovac Biotech Co., Ltd","companyId":"sinovac-biotech-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"This inactivated SARS-CoV-2 vaccine stimulates the immune system to produce antibodies and cellular immunity against the virus by presenting inactivated viral particles. Used for Prevention of COVID-19 caused by SARS-CoV-2.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}